Myelosuppression. With extreme caution should be used sustanon 350 in patients with severe myelosuppression as interferon alpha inhibits the bone marrow, causing a drop in the number of white blood cells (especially granulocytes), platelet count and, less commonly, hemoglobin levels. This may lead to an increased risk of infection or hemorrhage. It is necessary to closely monitor these developments and to conduct detailed patient blood tests before starting treatment and regularly in its process.
Infection. Fever may be associated with the flu-like syndrome, which is often observed during interferon therapy. When persistent fever, particularly in patients with neutropenia, infection should be excluded.The therapy with alpha interferons, including registered cases of serious infections (bacterial, viral, fungal). In the event of serious infectious complications should be discontinued interferon and assign appropriate therapy.
Ophthalmic changes. As in other interferon therapy, therapy with registered cases of retinopathy (retinal hemorrhages, cotton wool exudates, papilledema, thrombosis, central retinal arteries and veins) and rear ischemic neuropathy, which can lead loss of vision. When complaints about the deterioration of visual acuity or vision loss in these patients should be performed ophthalmologic examination. Patients with diabetes mellitus, hypertension before prescribing treatment is necessary to conduct an eye examination to detect the pathology of the fundus. Treatment ribavirin should be discontinued if deterioration occurs, or ophthalmic diseases.
Hypersensitivity reactions. During therapy with interferons, including interferon alfa-2a, there are severe reactions of immediate type hypersensitivity (urticaria, angioedema, bronchospasm and anaphylaxis).In the case of such reactions during therapy ribavirin therapy immediately cancel and prescribe the appropriate medication. Transient rashes do not require discontinuation of therapy.
Changes of endocrine organs. Rarely on background therapy sustanon 350 observed hyperglycemia. In the presence of clinical symptoms of hyperglycemia requires monitoring of blood glucose and appropriate monitoring. Patients with diabetes mellitus may require dose adjustment of antidiabetic drugs.
Autoimmune disorders. During therapy with alpha interferons registered cases of the formation of various autoantibodies. Clinical manifestations of autoimmune diseases with interferon therapy frequently occur in patients who are predisposed to development of such diseases.
Alpha interferon therapy is rarely associated with the onset or exacerbation of psoriasis. Patients after transplantation (e.g., kidney, or bone marrow) immunosuppressive drug may be less effective, since interferons have a stimulating effect on the immune system. As with other alpha interferons, in patients receiving , transplant rejection cases observed.
In combination therapy with ribavirin – see also precautions to ribavirin..
Instructions on the treatment of drug
Multi-dose cartridges 18 million IU per 0.6 ml intended for use by only one patient. They only apply to the injection pen penem. Together with syringe pen needle and cartridge only Penfayn be applied. For each injection, you should use a new sterile needle. Cartridges sustanon 350 should be used within 30 days after the first injection. After each injection, the pen with the inserted cartridge should be stored in the refrigerator, protected from light, but if necessary, the pen with the cartridge can be stored at room temperature (25 ° C) up to 28 days. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.